awmsg logo



C1 inhibitor (Cinryze®)


Reference No. 73

Publication date:
22/03/2013


Appraisal information

C1 inhibitor (Cinryze®) 500 units powder and solvent for solution for injection


Company: Shire Pharmaceuticals Ltd
BNF category: Respiratory system
NMG meeting date: 09/01/2013
AWMSG meeting date: 06/02/2013
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0313
Ministerial ratification: 18/03/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

C1 inhibitor (Cinryze®) is recommended as an option for use within NHS Wales for the treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema, and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema who are intolerant to or insufficiently protected by oral prevention treatments or who are inadequately managed with repeated acute treatment.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download